Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study

BackgroundGlucocorticoids are associated with increased fracture risk and are the mainstay of treatment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, fracture risk in these conditions has not been previously quantified. The aim of this study was to quantify the risk of fracture among patients with PMR and GCA.MethodsA retrospective cohort study was conducted using primary care records from the UK-based Clinical Practice Research Datalink. Individuals aged 40 years and over, with incident diagnoses of PMR or GCA were separately identified from 1990–2004 and followed up until 2015. For each exposed individual, four age-, sex- and practice-matched controls were randomly selected. Incidence rates of fracture per 10,000 person-years were calculated for each disease group and hazard rates were compared to the unexposed using Cox regression models.ResultsOverall, 12,136 and 2673 cases of PMR and GCA, respectively, were identified. The incidence rate of fracture was 148.05 (95% CI 141.16–155.28) in PMR and 147.15 (132.91–162.91) in GCA per 10,000 person-years. Risk of fracture was increased by 63% in PMR (adjusted hazard ratio 1.63, 95% CI 1.54–1.73) and 67% in GCA (1.67, 1.49–1.88) compared to the control populations. Fewer than 13% of glucocorticoid-treated cases were prescribed bisphosphonates.ConclusionsThis study reports, for the first time, a similar increase in fracture risk for patients with PMR and GCA. More needs to be done to improve adherence to guidelines to co-prescribe bisphosphonates. Further research needs to identify whether lower glucocorticoid starting doses and/or aggressive dose reduction reduces fracture risk.

[1]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[2]  V. Kyle,et al.  Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. , 1989, Annals of the rheumatic diseases.

[3]  C. Cooper,et al.  Incidence of clinically diagnosed vertebral fractures: A population‐based study in rochester, minnesota, 1985‐1989 , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  S. J. Preston,et al.  Methotrexate osteopathy in rheumatic disease. , 1993, Annals of the rheumatic diseases.

[5]  C. Cooper,et al.  Use of Inhaled Corticosteroids and Risk of Fractures , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  L Abenhaim,et al.  The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results , 2000, Pharmacoepidemiology and drug safety.

[7]  James M Robins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[8]  C. Cooper,et al.  Inflammatory bowel disease and the risk of fracture. , 2003, Gastroenterology.

[9]  I. Chantler,et al.  Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service , 2003, Annals of the rheumatic diseases.

[10]  W. Bilker,et al.  The relationship between time since registration and measured incidence rates in the General Practice Research Database , 2005, Pharmacoepidemiology and drug safety.

[11]  C. Cooper,et al.  Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[12]  L. Smeeth,et al.  Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001 , 2006, Annals of the rheumatic diseases.

[13]  S. Giannini,et al.  High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. , 2006, Bone.

[14]  P. Vestergaard,et al.  Methotrexate, Azathioprine, Cyclosporine, and Risk of Fracture , 2006, Calcified Tissue International.

[15]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[16]  K. Barraclough,et al.  BSR and BHPR guidelines for the management of polymyalgia rheumatica. , 2010, Rheumatology.

[17]  K. Barraclough,et al.  BSR and BHPR guidelines for the management of giant cell arteritis. , 2010, Rheumatology.

[18]  A. Iagnocco,et al.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.

[19]  M. Miccoli,et al.  Adverse Events During Longterm Low-dose Glucocorticoid Treatment of Polymyalgia Rheumatica: A Retrospective Study , 2012, The Journal of Rheumatology.

[20]  K. Chalkidou.  About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.

[21]  C. Cooper,et al.  Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom , 2013, Osteoporosis International.

[22]  I. Petersen,et al.  Monitoring of Patients on Long-Term Glucocorticoid Therapy , 2015, Medicine.

[23]  K. Barraclough,et al.  2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative , 2015, Arthritis & rheumatology.

[24]  B. Dasgupta,et al.  Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica , 2015, RMD Open.

[25]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[26]  S. Hider,et al.  Characterising those with incident polymyalgia rheumatica in primary care: results from the PMR Cohort Study , 2016, Arthritis Research & Therapy.

[27]  T. Helliwell.  Polymyalgia rheumatica in primary care : an exploration of the challenges of diagnosis and management using survey and qualitative methods , 2016 .

[28]  E. Matteson,et al.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities , 2017, Nature Reviews Rheumatology.

[29]  W. Grassi,et al.  Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. , 2017, Reumatismo.

[30]  J. Stone,et al.  Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. , 2017, Seminars in arthritis and rheumatism.